United States Court of Appeals
                            FOR THE EIGHTH CIRCUIT
                                     ___________

                                Nos. 97-4157/98-2525
                                    ___________

United States of America,                 *
                                          *
             Appellant,                   *
                                          * Appeals from the United States
      v.                                  * District Court for the Northern
                                          * District of Iowa.
Grand Laboratories, Inc.,                 *
a South Dakota Corporation;               *
Duane C. Pankratz,                        *
                                          *
             Appellees.                   *
                                     ___________

                              Submitted: November 16, 1998

                              Filed: May 4, 1999
                                    ___________

Before BEAM, LAY, and LOKEN, Circuit Judges.
                            ___________

BEAM, Circuit Judge.

       The United States appeals the district court's adverse rulings arising from claims
that Grand Laboratories, Inc. and Dr. Duane C. Pankratz violated the Virus-Serum-
Toxin Act (the VSTA) when Dr. Pankratz switched contaminated biological product
with a bogus substitute and transported the contaminated material. The district court
found that Dr. Pankratz violated the VSTA, but vindicated Grand Laboratories and
denied any injunction to restrain future violations of the VSTA. The district court
further found that the decision of the United States Department of Agriculture (the
USDA), to deny reprocessing of the contaminated product, was arbitrary, capricious,
and an abuse of discretion, and ordered reprocessing. We affirm in part and reverse
in part.

I.    BACKGROUND

       Dr. Duane Pankratz, a doctor of veterinary medicine, is the president and owner
of Grand Laboratories, Inc. (Grand Labs). Grand Labs manufactures veterinary
biological products and holds a federal establishment license subjecting Grand Labs to
regulation by the USDA. On June 23, 1989, Grand Labs obtained a federal license to
produce a biological product called Bovine Rhinotracheitis-Virus Diarrhea-
Parainfluenza 3-Respiratory Syncytial Virus Vaccine (trade name—Vira Shield 5).

       Between June 22 and 25, 1990, employees of Grand Labs mixed the component
parts of Vira Shield 5 to create a batch called serial 45-016. Serial 45-016 was then
placed in 3,896 plastic bottles. Federal law requires that each serial of the licensed
product be tested for viable bacteria and fungi. See 9 C.F.R. § 113.26. Initial testing
showed that serial 45-016 was contaminated. Although the alleged cost of making the
serial was $300,000, it was scheduled to be destroyed.

       When informed of the test results and the serial's impending destruction, Dr.
Pankratz instructed that the product not be destroyed until he gave the okay. He then
produced a worthless substitute solution, poured it into plastic bottles, packed the
bottles in boxes, labeled the boxes as serial 45-016, and switched the real serial with
the substitute concoction. He made the switch at about 3:00 a.m. and subsequently
transported the contaminated serial. Dr. Pankratz then gave the go-ahead to destroy
the bogus serial 45-016. But, after discovering that the material had been tampered
with, an employee of Grand Labs contacted the USDA to inform them that a
contaminated product was missing. The USDA inspected the facility and could not
locate the original serial 45-016. Dr. Pankratz later led the USDA inspectors to serial

                                         -2-
45-016, which by that time was located in a van in the parking lot. It had been left
unrefrigerated for some period of time.

      On October 15, 1990, in an effort to remove the contaminants and thereby allow
the sale of serial 45-016, Dr. Pankratz and Grand Labs submitted a request for
reprocessing to the USDA. The USDA outlined what would be required to permit
reprocessing: identification of the contaminants and a proposal for removing the
contaminants—including harmful metabolites or toxins. Dr. Pankratz submitted several
subsequent tests of the serial and presented proposals for reprocessing. After almost
two years of review and subsequent testing, the USDA denied the request to reprocess.
Thus, serial 45-016 has remained under quarantine at Grand Labs since October 1990.

       The United States filed civil charges against Dr. Pankratz and Grand Labs in
November 1991 for violations of the VSTA. Dr. Pankratz, objecting to the USDA's
decision denying reprocessing, counterclaimed under the Administrative Procedure Act.
5 U.S.C. §§ 551 et seq. After trial, the district court concluded, inter alia, that Dr.
Pankratz was liable for shipping a contaminated biological product in violation of the
VSTA, but that Grand Labs was not. The district refused to order a permanent
injunction against either Dr. Pankratz or Grand Labs to prevent future violations of the
VSTA. The court also concluded that serial 45-016 should not be destroyed, but
instead ordered the USDA to allow reprocessing.

II.   DISCUSSION

      The parties have raised three primary issues on appeal: (1) the liability of Grand
Labs for Dr. Pankratz's actions; (2) the USDA's denial of reprocessing; and (3) the




                                          -3-
issuance of an injunction against Dr. Pankratz and Grand Labs.1 We consider each
separately.

      A.     Grand Lab's Liability

       The complaint alleges that Dr. Pankratz, "acting on behalf of Grand Labs,"
violated the VSTA, and seeks injunctive relief against both. The district court found
that Dr. Pankratz violated the VSTA, but without discussion held that Grand Labs had
not. The United States contends that this is error, citing basic agency principles.
Grand Labs argues that the district court did not err because all the evidence "put on
by the Government to support injunctive relief related to what Dr. Pankratz did and did
not do." We review this question of law de novo. See Long v. Nix, 

, 764-
65 (8th Cir. 1996).

       Dr. Pankratz, as president and owner of Grand Labs, violated the VSTA when
he transported a contaminated biological product. "The general rule is that a
corporation is liable for the torts and wrongful acts of its employees acting within the
scope of their authority or the course of their employment." United States v. United
States Cartridge Co., 

, 464 (8th Cir. 1952). This general principle of
vicarious liability demands that liability be imputed to Grand Labs. Thus, the district
court erred with respect to Grand Labs' liability.

      B.     Reprocessing

      After serial 45-016 tested positive for contamination, the USDA placed it under
quarantine pending final resolution of this action. Dr. Pankratz and Grand Labs then
sought to reprocess the serial to allow its sale. To support the reprocessing request,


      1
       We have carefully reviewed the record and find no merit to arguments not
discussed herein.

                                          -4-
Grand Labs conducted several subsequent tests of the serial and alleged that the
contamination shown by the initial test may have resulted from employee misconduct.
However, the USDA denied the reprocessing request despite Grand Labs' evidence.
The gist of the USDA's position is summarized in a letter to Dr. Pankratz that states:

      The results of your latest testing do not negate the fact that the serial was
      found to be contaminated at the time of the initial sterility testing. Since
      the organism has not been identified, there is no way to determine what
      metabolites or toxins were produced by the contaminant.

      You have not proposed an acceptable way to remove the contaminant
      from the serial, nor to test for possible harmful metabolites or toxins. I
      cannot grant an approval for your reprocessing request.

Appellant's Appendix at 79.

        Dr. Pankratz and Grand Labs successfully argued to the district court that the
agency's denial constituted arbitrary and capricious conduct. We, like the district court,
review the agency's decision to deny reprocessing to determine if the decision was
"'arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with
law.'" Wilkins v. Secretary of the Interior, 

, 852-53 (8th Cir. 1993)
(quoting 5 U.S.C. § 706(2)(A)). This limited review dictates that we not substitute our
judgment for that of the agency, but instead requires that we "give substantial deference
to agency determinations." Downer v. United States, 

, 1002 (8th Cir.
1996) (per curiam). Substantial deference is particularly appropriate where, as here,
the agency's decision concerns a subject within its unique area of expertise. See 

states that "in the interest of justice there is little to lose and
everything to gain by affirming the district court" on this issue. Post at 14. This is, of
course, not the proper standard of review for agency determinations. Furthermore,
deference to an agency determination is all the more compelling in a case such as this,

                                           -5-
where the district court itself concluded that "the testimony of the witnesses on both
sides as to whether or not serial 45-016 was contaminated was very impressive."
United States v. Grand Lab., Inc., No. C 91-4113-DEO, mem. op. at 28 (N.D. Iowa
Aug. 14, 1996). The district court's statement highlights the very dilemma put before
the USDA in its consideration of whether to allow reprocessing of serial 45-016–to
believe the evidence supporting contamination or the evidence suggesting no
contamination.

       The evidence supporting contamination rests on the first test conducted by Grand
Labs. The USDA's experts reviewed the test and test procedures and concluded that
the results were accurate. It should also be remembered that based upon this initial
test, the district court found Dr. Pankratz liable for shipment of a contaminated
biological product, a point not challenged on appeal. In the nearly nine years since
serial 45-016 was produced and over six years since the denial of reprocessing, Dr.
Pankratz and Grand Labs have sought to undermine the validity of the initial test
through subsequent testing and allegations of employee misconduct. Not all subsequent
tests were in the administrative record, but contrary to the dissent’s position, there were
tests showing no contamination which were considered by the USDA in its
reprocessing decision. Additionally, the USDA had evidence before it that suggested
employees of Grand Labs had somehow "set-up" Dr. Pankratz. The administrative
record, although not as richly developed as the trial court record, provided sufficient
evidence for the USDA to make a rational reprocessing decision.

       With evidence on both sides, including expert testimony, the USDA was left
with the difficult decision of whether to allow or deny reprocessing. If reprocessing
were allowed and any remnants of an unidentified contaminate–dead bacteria,
metabolites or toxins—were not discovered and removed (a possibility since the USDA
knows no way to test and remove them, and Grand Labs provided no suitable
suggestions), then there would be a green light to market the product. Serial 45-016
could then be administered to thousands of head of livestock.

                                           -6-
       The other alternative was to deny reprocessing based on the initial test showing
contamination and thereby err on the side of public safety.2 The USDA followed their
experts and chose the path of public safety. An agency making determinations that are
so wrapped-up with scientific judgments must be permitted to rely upon the
"'reasonable opinions of its own qualified experts.'" 

(quoting
Marsh v. Oregon Natural Resources Council, 

, 378 (1989)).

       The USDA's experts were concerned, as indicated, about unidentified
contaminants in serial 45-016 as well as metabolites and toxins that the contamination
may have produced. These concerns persisted throughout the reprocessing request and
were not alleviated by Dr. Pankratz and Grand Labs. Thus, the reprocessing request
was denied. "'[E]ven if, as an original matter, a court might find contrary views more
persuasive,'" the USDA's determination is not arbitrary, capricious, or an abuse of
discretion and must be given deference. 

490 U.S. at 378).
Therefore, we uphold the USDA's determination on reprocessing.

      C.     Injunction

       As noted, the complaint seeks a permanent injunction restraining Grand Labs and
Dr. Pankratz from "violating the VSTA and its implementing rules and regulations
including, but not limited to: . . . (3) shipping or delivering for shipment any worthless,
contaminated . . . product." The United States argues that an injunction is necessary
to protect the public health and safety and to prevent the likely recurrence of what was
"not an isolated incident." The United States essentially seeks two injunctions: one for
restraining the shipment of serial 45-016 and another for any future violation of the law.
The district court denied any injunctive relief, concluding that there is little or no


      2
      The USDA no longer authorizes reprocessing to eliminate contamination in a
product. See United States Department of Agriculture, Veterinary Service
Memorandum No. 880.62 (December 10, 1997).

                                           -7-
possibility of future violations that ordinary enforcement would not adequately remedy.
We review for abuse of discretion. See United States v. Green Acres Enter., Inc., 

, 132 (8th Cir. 1996).

       Injunctive relief is generally appropriate when there is no adequate remedy at
law. See Hockenberg Equip. Co. v. Hockenberg's Equip. & Supply Co. of Des
Moines, Inc., 

, 158 (Iowa 1993). "Probably the most common method
of demonstrating" that a legal remedy is inadequate is by showing that irreparable harm
will result. 11A Charles Alan Wright et al., Federal Practice and Procedure § 2944, at
90 (2d ed. 1995); see also Green 

.

       We find that shipment of serial 45-016 presents an appropriate situation for
injunctive relief. Dr. Pankratz has demonstrated a willingness to circumvent
established procedures and legal constraints to salvage a costly but contaminated
biological product. If serial 45-016 is shipped and sold, tremendous damage could
result. And since we have upheld the USDA's decision to deny reprocessing, we
conclude that an injunction should issue restraining Dr. Pankratz and Grand Labs from
shipment of serial 45-016.

       Injunctive relief for any future violations of the law, however, presents a different
analysis. The district court noted that even counsel for the United States characterized
this request as essentially "a situation where the Government is seeking an injunction
from the Court to require Grand to follow the law." Grand Lab., memorandum op. at
49. While there are scenarios "where Congress expressly provides for injunctive relief
to prevent violations of a statute," such is not the case here. Burlington N. R.R. Co.
v. Bair, 

, 601 (8th Cir. 1992) (analyzing section 306 of the Railroad
Revitalization and Regulatory Reform Act of 1976). Ordinary enforcement of the
VSTA, although not nearly as simple as a contempt proceeding that would result from
a violation of an injunction, is an adequate legal remedy. An injunction should not
ordinarily issue simply because a law has been violated.

                                            -8-
III.   CONCLUSION

     For the foregoing reasons we affirm in part and reverse in part the district court's
judgment and remand for further proceedings consistent with this opinion.

LAY, Circuit Judge, dissenting.

       The majority opinion holds that the district court erred by substituting its opinion
for that of the USDA when it reversed the USDA’s denial of Grand Labs’ request to
reprocess serial 45-016. I respectfully submit that the majority opinion reflects a basic
misunderstanding of the district court’s holding. The district court found that the
USDA’s denial of reprocessing was arbitrary and capricious because the USDA failed
to review a full and fair administrative record when it decided the serial could not be
retested to determine whether it could be safely marketed to the public. In so holding,
the district court was simply following the Supreme Court’s dictate in Florida Power
& Light Co. v. Lorion, 

, 744 (1985):

       If the record before the agency does not support the agency action, if the
       agency has not considered all relevant factors, or if the reviewing court
       simply cannot evaluate the challenged agency action on the basis of the
       record before it, the proper course, except in rare circumstances, is to
       remand to the agency for additional investigation or explanation.


Thus, it is a fundamental misconception to say that the district court substituted its own
judgment for that of the USDA where the USDA’s judgment was not based on
consideration of all the relevant factors.

        The majority’s confusion probably arises from the rather unusual procedural
history of this case. This action originally arose when the USDA brought a four-count
civil suit against Dr. Pankratz and Grand Labs for violations of the Virus-Serum-Toxin

                                           -9-
Act (VSTA). The defendants filed a counterclaim under the Administrative Procedure
Act (APA), 5 U.S.C. §§ 551 et seq., challenging the USDA’s decision to deny their
requests for reprocessing of serial 45-016. The court initially granted the government’s
motion for summary judgment on the defendants’ counterclaim and upheld the USDA’s
decision to deny reprocessing. The court granted the USDA’s motion for summary
judgment for three basic reasons. First, the USDA had explained that the contaminant
discovered in the serial in the original test might have produced toxins or metabolites
that could not be identified or removed. Second, the defendants had presented no
evidence to indicate that the original test could be questioned. Third, the USDA
showed that the product had gone unrefrigerated when Dr. Pankratz removed it, and
that lack of refrigeration alone would justify the agency’s denial of the reprocessing
request.

       The district court then proceeded to trial on the other counts. After trial, the
district court found liability on only one count of the complaint (shipment of a
contaminated biological product).3 The district court then reversed its earlier grant of
summary judgment for the government on the counterclaim and ordered that the USDA
expand its administrative record to include all relevant factors relating to the grant or
denial of reprocessing. The court found that evidence disclosed at trial showed that the
USDA had not considered relevant evidence that serial 45-016 was not contaminated
when it made its decision to deny reprocessing.4 On this basis, the court ordered that

      3
       The defendants were found not responsible for falsely labeling a biological
product; for not having suitable tags or labels on a biological product; and for shipping
a worthless product.
      4
          The district court stated:

      The USDA, as shown in the letters above, had taken a position that the
      first test, Exhibit A-1, of serial 45-016 showed contamination. Thereafter,
      they consistently held the position that no retesting could be done until
      such time as Grand could identify what the contaminant had been and

                                          -10-
the case be remanded to the USDA in light of the overall record not previously
considered by the USDA at the time of its original decision. The district court
emphasized that the decision whether the serial would ultimately be placed on the
market for sale would be made only by the USDA , but only after full and fair review
testing. This appeal arises primarily from the district court’s decision on this
counterclaim.

        It is important to set forth this procedural history because it points out that the
district court was not substituting its judgment for the USDA, but rather was simply
requiring a full and fair review based upon the testimonial record developed in the
district court. I mention this because it is not the prerogative of the district court in
reviewing agency action under the APA to make a new record and overrule the
agency’s decision based upon evidence that the agency has not reviewed. See Camp
v. Pitts, 

, 142 (1973); Wilkins v. Secretary of Interior, 

, 853
(8th Cir. 1993). Contrary to the implicit holding of the majority opinion, the district
court did not do this in the present case. The procedural history is also important to
emphasize that the ultimate issue here is not the question of reprocessing, but whether
the agency should be required to consider the entire record, including the results of
current and concurrent testing, in making the ultimate decision whether the serial is safe
for consumer use.




      successfully demonstrate that whatever the contaminant was, it was all
      now removed from serial 45-016. This is an impossible position because
      it assumes there was contamination. Grand made tests (Exs. I-1, O-1, L-
      1, H-2, V-2, E-3, G-3, A-4, B-4), all of which were negative for
      contamination (Trial Tr. 344). None of these were part of the
      administrative record and therefore were never considered by the USDA.

United States v. Grand Labs., Inc., No. C91-4113-DEO, at 37 (N.D. Ia. Sept. 22,
1997)(order).

                                           -11-
        The majority opinion does not discuss the evidence the district court relied upon
to conclude that its original grant of summary judgment should be vacated and that
further tests should be done. I believe this evidence supported the district court’s
decision. The USDA based its position that serial 45-016 is contaminated solely on the
results of the first sterility test performed on September 25, 1990. As the district court
found, however, the testimony developed at trial casts grave doubt upon the reliability
of that original test showing contamination of serial 45-016. 5 There was testimony that


      5
      The district court set out the reasons why the first test showing contamination
was questionable:

      “While the government would urge the Court to accept the contamination
      of serial 45-016 as set out in Exhibit A-1, it should be noted that Robin
      Moffle and Wayne Behan rushed to tell the government about that test
      and the moving of that serial, and acted as though they were carrying out
      their duty as in-house USDA representatives at Grand. (Tr. 634.) At
      least part of the eagerness for this conduct is that Ms. Moffle admitted
      that she hated Dr. Pankratz. (Tr. 357.) Thomas Miller, Grand Central
      Services Manager, admitted that he and Moffle agreed to lie to Dr.
      Pankratz about the destruction of serial 45-016. (Tr. 423.) Behan and
      Moffle did not report other things to the government that would have
      shown that there were two sides to the contamination question. They did
      not tell USDA officials that Dr. Pankratz had told Behan he wanted to
      save serial 45-016 so that it could be reprocessed. They did not reveal
      that Exhibit 28 showed the product 45-016 in bulk was not contaminated.
      The plaintiff tries to minimize this omission by saying Dr. Pankratz also
      did not tell the USDA about Exhibit 28. However, USDA did not ask
      him for test information. They were then listening to a ‘bad’ report by
      Moffle which left out anything favorable. (Tr. 1433.) Ms. Moffle, when
      asked about this, said that she forgot to tell the USDA that. Moffle and
      Behan further did not report that they started another sterility test in secret
      on October 19, 1990 on the same samples as used in the first test, and on
      November 2, 1990, the results showed that the product was sterile. (Ex.
      I-1.) After this test was completed, Ms. Moffle did not have it written up
      as shown in Exhibit I-1 until almost a year later, when Dr. Pankratz heard

                                           -12-
concurrent tests were performed at Grand Labs in September, October and November
which showed no contamination, and that Dr. Pankratz’s employees did not report
these satisfactory tests to the USDA.6 In fact, a second bulk sterility test was
performed on the serial on September 26, 1990, the day after the initial test, and it
showed no contamination. Yet the USDA was not informed of this satisfactory test.
The district court also received testimony from Dr. Long, a former USDA official, that
safety tests had been performed on serial 45-016 which found the serial to be free from
any substance toxic enough to cause any reaction to an animal. Finally, the court found
that the government failed to prove that serial 45-016 had gone unrefrigerated for any
extended period of time as it had previously alleged.7 This evidence, however, was not
in the administrative record before the USDA and was never considered by the USDA
when it denied reprocessing. Therefore, the district court concluded that the USDA
failed to consider important evidence to form a rational basis for its denial of Grand




       about it and insisted that it be properly written up. (Tr. 610.) The
       defendants contend with some credence that the reason for these
       omissions was that they discredited and/or certainly questioned the
       reliability of the first test, Ex. A-1, which, of course, is the bottom line for
       all of this litigation.”

United States v. Grand Labs., Inc., No. C91-4113-DEO, at 30 (N.D. Ia. Sept. 22,
1997) (order) (quoting its earlier order of Aug. 14, 1996, at 55 n.13).
       6
        The district court found that the employees failed to report these satisfactory test
results to the USDA because they disliked Dr. Pankratz.
       7
        In any event, the experts acknowledged that lack of refrigeration is relevant to
the question of potency, and that upon retesting it could be determined whether lack of
refrigeration had any effect on the potency of serial 45-016. Ultimately, potency may
very well affect the decision whether the serial can be marketed. However, this can
only be discovered upon retesting of the serial.

                                            -13-
Labs’ requests for reprocessing serial 45-016.8 The USDA’s failure to consider this
evidence justified the district court’s order remanding the case to the USDA for
retesting and reconsideration of serial 45-016's marketability based upon all of the
relevant evidence.9

       It may seem cavalier to say that in the interest of justice there is little to lose and
everything to gain by affirming the district court. There is no question that Dr. Pankratz
concealed the alleged contaminated product and substituted a bogus product in its
place; his conduct clearly should not be condoned.10 However, affirming the district


       8
           The district court stated:

       The court finds that the agency did not fully consider several things it
       should have. These include but are not limited to fair consideration of the
       request to reprocess, that the agency ignored the regulations concerning
       the right of the defendants in matters involving quarantine and no-test, and
       acted arbitrarily and capriciously toward the legitimate requests of the
       defendants in that the administrative record was inadequate and there was
       no rational relationship between the evidence and their decision not to
       allow any reprocessing, and, as found here and in this court’s order of
       August 14, 1996, serial 45-016 has not been fully and carefully tested.

United States v. Grand Labs., Inc., No. C91-4113-DEO, at 51 (N.D. Ia. Sept. 22,
1997) (order).
       9
       I find it is highly significant that the district court evaluated the new evidence
from 4,000 pages of testimony and considered the evidence to be such that the USDA
should consider it in determining whether serial 45-016 is marketable.
       10
         Although they do not excuse Dr. Pankratz’s conduct, several facts help to
explain it. It is clear from the record that Dr. Pankratz’s sole motive in concealing
serial 45-016 and substituting it with a bogus serial was to preserve the serial for
retesting. Grand Labs had invested $300,000 in the serial and it was the company’s
most important product. He had falsely been told by his employees that the USDA
intended to destroy the allegedly contaminated product, and his employees had

                                            -14-
court’s order of reprocessing would not threaten the safety of animals. The district
court specifically stated that it was not ordering the USDA to allow Grand Labs to
market serial 45-016. Rather, it only ordered it to allow Grand Labs to spend $40,000
of its own money to retest the serial and then submit the evidence of this retest, along
with the testimony developed at trial and the satisfactory test results withheld from the
USDA, for reconsideration by the USDA in light of the overall record. The bottom line
is that the USDA retains the ultimate decision whether serial 45-016 may be marketed,
and its decision will remain undisturbed as long as it was made based upon full and fair
consideration of the record. If the government is still convinced after reprocessing that
the original finding of contamination is irrevocable, it can simply deny Grand Labs the
right to market the serial, and we will be back at square one. By allowing reprocessing,
however, Grand Labs will be assured that the government is giving it a full and fair
opportunity to urge its position that serial 45-016 is marketable.

       For these reasons, I would affirm the district court. I respectfully submit that it
is unreasonable to find that a district court erred by requiring an administrative agency
to fully and fairly review all the evidence in making its critical decisions.




Injunctive Relief

       I respectfully submit that the district court’s decision denying all injunctive relief
also should be upheld. The question whether a plaintiff is entitled to injunctive relief
in a given case “addresses itself to the judicial discretion of the trial court,” Columbia
Transit Corp. v. Jones, 

, 173 (8th Cir. 1978), and should be given due
deference by this court. One of the requirements necessary for injunctive relief to be


concealed from the USDA tests that showed no contamination.

                                            -15-
granted, is that the plaintiff has no adequate remedy at law. See, e.g., 

clear
in this case that the USDA has an adequate remedy at law in the event of any future
shipment of serial 45-016 or other VSTA violation by Dr. Pankratz.

       Under 21 U.S.C. § 157, an adequate legal remedy exists for the USDA to enter
any establishment where any virus, serum, toxin or other product used in the treatment
of domestic animal is prepared, at any hour of the day or night to inspect and enforce
compliance. I fail to see how an injunction in any way would create a greater
deterrence from VSTA violation than does the statute itself. Furthermore, Dr.
Pankratz’s conduct appears to be an isolated act, and the record reveals no basis for
concluding that any likelihood exists that he will ship serial 45-016 again.

      For the foregoing reasons, I dissent.

      A true copy.

             Attest:

                CLERK, U.S. COURT OF APPEALS, EIGHTH CIRCUIT.




                                         -16-